Effectiveness and safety of combined iron-chelation therapy with deferoxamine and deferiprone (Journal article)

Alymara, V./ Bourantas, D./ Chaidos, A./ Bouranta, P./ Gouva, M./ Vassou, A./ Tzouvara, E./ Bourantas, K. L.

INTRODUCTION: The purpose of our study was to evaluate the effectiveness and safety of combined therapy with deferoxamine (DFO) and deferiprone (DFP) in patients with beta-thalassemia major and increased serum ferritin. PATIENTS AND METHODS: Our study was performed in 36 patients with beta-thalassemia major. DFP was administered orally in a total daily dose of 60 mg/kg for 6 days per week and DFO was administered subcutaneously in a total daily dose of 40-50 mg/kg for 4-6 days per week. The efficacy of combined treatment was assessed by measurements of serum ferritin and 24-h urine iron excretion levels. RESULTS: Out of the 36 patients, 11 discontinued DFO after a mean of 4 months; however, 25 patients, who continued to receive the combined therapy showed a very satisfactory compliance. After a mean of 13.5 months, their mean serum ferritin levels reduced from 2637 + 1292 to 1580 + 1024 ng/ml (P = 0.002) and their mean urinary iron excretion elevated from 0.41 + 0.27 to 0.76 +0.49 mg/24h (P = 0.003). The observed side effects were gastrointestinal disorders,elevations in liver enzymes, mild neutropenia, joint symptoms, taste disorders, dizziness and fatigue. CONCLUSIONS: The results of this study show that combined iron-chelation therapy with DFO and DFP results in satisfactory reduction of serum ferritin with no significant toxicity.
Institution and School/Department of submitter: Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής
Keywords: Administration, Oral,Adolescent,Adult,Deferoxamine/*administration & dosage/adverse effects,Dose-Response Relationship, Drug,Drug Administration Schedule,Drug Therapy, Combination,Female,Ferritins/blood/drug effects,Humans,Injections, Subcutaneous,Iron/urine,Iron Chelating Agents/*administration & dosage/adverse effects,Male,Middle Aged,Pyridones/*administration & dosage/adverse effects,Treatment Outcome,beta-Thalassemia/*drug therapy
URI: https://olympias.lib.uoi.gr/jspui/handle/123456789/22145
ISSN: 1466-4860
Link: http://www.ncbi.nlm.nih.gov/pubmed/15570288
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά)

Files in This Item:
There are no files associated with this item.


 Please use this identifier to cite or link to this item:
https://olympias.lib.uoi.gr/jspui/handle/123456789/22145
  This item is a favorite for 0 people.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.